Postpartum HemorrhageNCT02604602
Coagulation Factors and Postpartum Hemorrhage
An observational study of Postpartum Hemorrhage, run by University of Zurich at 1 site in Switzerland.
Trial summary
Objective is to analyze a possible association of coagulation factors peripartal with the occurrence of postpartum hemorrhage. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Postpartum Hemorrhage
- What is being tested?
- blood exam
- How many people
- 1,500 participants
- Where
- 1 siteSwitzerland
- Study dates
- Oct 2015to 20 Apr 2020
- How long will I take part?
- 2 Weeks
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: pregnant women before delivery
Who may be able to join
- pregnant women > 22 weeks of gestation
Who cannot join
- age < 18 years, no informed consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Peripartal Concentration of Coagulation Factors and Postpartum Hemorrhage
Objective is to analyze a possible association of coagulation factors peripartal with the occurrence of postpartum hemorrhage.
- Conditions
- Postpartum Hemorrhage
- Being tested
- blood exam
- Keywords
- PPH
- Medical subject headings
- Postpartum Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood examOther
laboratory test
| Study group | Role | What they receive |
|---|---|---|
| PPH | Not described Receives: Other: blood exam | |
| non-PPH | Not described Receives: Other: blood exam |
What is being measured
The primary outcome is the main question the study is designed to answer.
occurrence of PPH
Measured: 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Nov 2015 (estimated)
- Study startOct 2015
- Primary completionNov 2018
- Study completion20 Apr 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Postpartum HemorrhageStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,500 participants (actual)
- Target duration
- 2 Weeks
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Christian Haslinger, M.D., Principal investigator, Division of Obstetrics, University Hospital of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02604602
- Sponsor's protocol ID
- KEK-ZH-Nr. 2015-0011
- Status last verified
- Apr 2020
- First submitted
- 11 Nov 2015
- Last updated
- 22 Apr 2020
- Results posted
- No
- Data monitoring committee
- No
Publications
Ranieri E, Korte W, Brandi G, Kalimeris S, Ochsenbein N, Haslinger C. D-Dimer levels during pregnancy and postpartum: non-applicability of regularly used cut-offs for diagnosis of suspected pulmonary embolism. Arch Gynecol Obstet. 2026 Feb 24;313(1):109. doi: 10.1007/s00404-026-08328-z.
PubMed 41733712
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Peripartal Concentration of Coagulation Factors and Postpartum Hemorrhage
- ClinicalTrials.gov ID
- NCT02604602
- Acronym / sponsor ID
- KEK-ZH-Nr. 2015-0011
- Conditions
- Postpartum Hemorrhage
- Keywords
- PPH
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,500 participants (actual)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Study start
- Oct 2015
- Primary completion
- Nov 2018 (actual)
- Study completion
- 20 Apr 2020 (actual)
- First posted
- 13 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective is to analyze a possible association of coagulation factors peripartal with the occurrence of postpartum hemorrhage.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Weeks
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PPH | – | Other: blood exam |
| non-PPH | – | Other: blood exam |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- pregnant women before delivery
Key inclusion criteria (1 listed)
- pregnant women > 22 weeks of gestation
Key exclusion criteria (1 listed)
- age < 18 years, no informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood examlaboratory test | Other | PPH, non-PPH |
Primary outcome
occurrence of PPH
Time frame: 7 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2020.
- Derived from this study: PubMed 41733712Ranieri E, Korte W, Brandi G, Kalimeris S, Ochsenbein N, Haslinger C. D-Dimer levels during pregnancy and postpartum: non-applicability of regularly used cut-offs for diagnosis of suspected pulmonary embolism. Arch Gynecol Obstet. 2026 Feb 24;313(1):109. doi: 10.1007/s00404-026-08328-z.
Related trials for Postpartum Hemorrhage
RecruitingObservational study
Long Term Outcome After Use of Vacuum-induced Tamponade for Postpartum Hemorrhage
Postpartum Hemorrhage, Treatment Outcome
Not yet recruitingObservational study
Measured Versus Hemoglobin-Calculated Postpartum Blood Loss in Waterbirth
Postpartum Hemorrhage, Waterbirth
RecruitingPhase 2
Prevention of Postpartum Hemorrhage With Tranexamic Acid
Post Partum Hemorrhage
RecruitingObservational study
Hemoglobin Testing in Pregnant Patients
Post Partum Hemorrhage, Anemia of Pregnancy
RecruitingPhase 4
Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial
Postpartum Hemorrhage, Uterine Atony
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christian Haslinger, M.D. principal investigator
Division of Obstetrics, University Hospital of Zurich
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Postpartum Hemorrhage, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
occurrence of PPH (time frame: 7 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02604602, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2020.